GlaxoSmithKline Stock News

Complete study of the global Methoxamine market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding of the present

Another exploration Titled "Worldwide Asthma Treatment Drugs 2019-Market Research Report" gives the Professional and inside and out assessment of extent of momentum and future market and survey of Product Specification, showcase pattern , item type and creation investigation considering central

Nigeria’s equities market opened this new week on a positive note as investors showed notable interests in stocks like MTNN, GlaxoSmithKline, and others. The stock market of Africa’s largest economy increased by 1.26percent or N276billion at the close of Monday’s trading session, pushing this year’s positive return to new high of 5.32percent and month-to-date (MtD) […]

New Jersey, United States,- Verified Market Research has recently published a research report titled, Healthcare Associated Infections Treatment Market Size, and Forecast 2021-2028, Breakdown Data by Manufacturers, Key Regions, Types and Application. Primary and secondary research methodologies have been used

Fisher Asset Management LLC lifted its stake in shares of GlaxoSmithKline plc (NYSE:GSK) by 1.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 17,830,400 shares of the pharmaceutical companys stock after buying an additional 282,409 shares during the quarter. Fisher Asset Management LLC []

Independence Bank of Kentucky lessened its position in shares of GlaxoSmithKline plc (NYSE:GSK) by 9.6% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 30,919 shares of the pharmaceutical companys stock after selling 3,270 shares during the period. Independence Bank of Kentuckys holdings in []

Highland Capital Management LLC reduced its holdings in GlaxoSmithKline plc (NYSE:GSK) by 2.4% during the third quarter, HoldingsChannel reports. The institutional investor owned 78,718 shares of the pharmaceutical companys stock after selling 1,900 shares during the period. Highland Capital Management LLCs holdings in GlaxoSmithKline were worth $3,008,000 as of its most recent filing with the []

West Family Investments Inc. increased its holdings in GlaxoSmithKline plc (NYSE:GSK) by 9.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,079 shares of the pharmaceutical companys stock after buying an additional 1,148 shares during the period. West []

Optimum Investment Advisors cut its holdings in shares of GlaxoSmithKline plc (NYSE:GSK) by 60.1% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,500 shares of the pharmaceutical companys stock after selling 5,275 shares during the quarter. Optimum Investment Advisors holdings in GlaxoSmithKline were []

GlaxoSmithKline plc (LON:GSK) reached a new 52-week high during trading on Thursday . The company traded as high as GBX 1,604.80 ($21.28) and last traded at GBX 1,597.21 ($21.18), with a volume of 1941934 shares. The stock had previously closed at GBX 1,591.80 ($21.11). A number of equities research analysts have recently commented on the [] The post GlaxoSmithKline (LON:GSK) Hits New 52-Week High at $1,604.80 appeared first on ETF Daily News .

The Goldman Sachs Group set a GBX 2,000 ($26.52) target price on GlaxoSmithKline (LON:GSK) in a report released on Tuesday, Borsen Zeitung reports. Several other research firms also recently weighed in on GSK. Deutsche Bank Aktiengesellschaft reissued a hold rating and set a GBX 1,350 ($17.90) price target on shares of GlaxoSmithKline in a research []

GlaxoSmithKline plc (NYSE:GSK) Equities research analysts at Jefferies Financial Group decreased their FY2021 earnings estimates for shares of GlaxoSmithKline in a research note issued on Tuesday, December 7th. Jefferies Financial Group analyst P. Welford now expects that the pharmaceutical company will earn $2.87 per share for the year, down from their prior estimate of []

Global Anti-Snoring Treatment Market has potentials to grow as the most influential market worldwide as it has been playing a noteworthy role in imprinting positive impacts on the international economy. The Global Anti-Snoring Treatment Market Report offers vital insights to

Howland Capital Management LLC decreased its position in shares of GlaxoSmithKline plc (NYSE:GSK) by 10.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,412 shares of the pharmaceutical company’s stock after selling 640 shares during the period. Howland Capital Management LLC’s holdings in […]

Howland Capital Management LLC lowered its position in GlaxoSmithKline plc (NYSE:GSK) by 10.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,412 shares of the pharmaceutical companys stock after selling 640 shares during the quarter. Howland Capital Management LLCs holdings []